Samuel Denmeade

Q: What Schools Are Affiliated With Samuel Denmeade

Samuel Denmeade is affiliated with the following schools: Institute of Cancer Research, Royal Veterinary and Agricultural University, Johns Hopkins University, Aichi Medical University

Samuel Denmeade's AcademicInfluence.com Rankings

Samuel Denmeade

Medical

#2419

World Rank

#2843

Historical Rank

Oncology

#239

World Rank

#247

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Samuel Denmeade Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Samuel Ray Denmeade is a Professor of Oncology, Urology and Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine. Over 10 of his published papers have each been cited over 100 times.

(See a Problem?)

Samuel Denmeade's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. (2014) (2191)
A history of prostate cancer treatment (2002) (552)
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer (2020) (494)
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer (1996) (460)
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. (2010) (413)
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. (2015) (373)
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. (2017) (354)
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. (2003) (274)
The SERCA pump as a therapeutic target: Making a “smart bomb” for prostate cancer (2005) (224)
Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. (1997) (222)
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study (2015) (207)
Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. (1997) (202)
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. (2017) (185)
Rationale Behind Targeting Fibroblast Activation Protein–Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy (2012) (184)
Engineering a Prostate-Specific Membrane Antigen–Activated Tumor Endothelial Cell Prodrug for Cancer Therapy (2012) (182)
Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. (1998) (164)
Concise Review: Mesenchymal Stem Cell‐Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise (2018) (162)
Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. (2012) (157)
Knockin of mutant PIK3CA activates multiple oncogenic pathways (2009) (145)
Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models (2003) (134)
Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin (2009) (130)
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. (2018) (129)
Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. (2001) (128)
Complete androgen blockade for prostate cancer: what went wrong? (2000) (120)
Thapsigargin induces a calmodulin/calcineurin‐dependent apoptotic cascade responsible for the death of prostatic cancer cells (2000) (118)
Concentration of enzymatically active prostate‐specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models (2001) (112)
Targeting thapsigargin towards tumors (2015) (110)
The N-Myc Down Regulated Gene1 (NDRG1) Is a Rab4a Effector Involved in Vesicular Recycling of E-Cadherin (2007) (109)
Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours (2016) (109)
Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers (2006) (105)
CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. (2003) (105)
Use of Methotrexate-Based Peptide Substrates to Characterize the Substrate Specificity of Prostate-Specific Membrane Antigen (PSMA) (2004) (101)
Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? (2007) (99)
Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer (2010) (98)
A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. (2007) (92)
Adaptive auto‐regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer (2012) (91)
Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. (2001) (89)
A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. (2006) (86)
A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells. (2009) (86)
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE) (2017) (84)
Development of prostate cancer treatment: The good news (2004) (83)
Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer (2009) (82)
Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death (2017) (82)
Assessment and validation of a microinjection method for kinetic analysis of [Ca2+]i in individual cells undergoing apoptosis. (1999) (81)
A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination (2015) (81)
A supramicromolar elevation of intracellular free calcium ([Ca2+]i) is consistently required to induce the execution phase of apoptosis (2002) (80)
Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. (2008) (76)
Quantification of Mesenchymal Stem Cells (MSCs) at Sites of Human Prostate Cancer (2012) (74)
Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells. (2006) (73)
Efficient triple coupling reaction to produce a self-adjusting molecular cage (1985) (73)
Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects. (2019) (70)
Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin (1997) (67)
In Vivo activity of a PSA‐activated doxorubicin prodrug against PSA‐producing human prostate cancer xenografts (2000) (66)
Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells. (1999) (66)
Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. (2011) (66)
Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. (2013) (63)
Combinatorial androgen receptor targeted therapy for prostate cancer. (2006) (61)
Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen. (2008) (61)
Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells. (2000) (61)
Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. (2013) (60)
A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. (2016) (60)
Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study (2016) (57)
Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage. (2019) (57)
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer (2010) (57)
Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)‐activated thapsigargin prodrug (2006) (50)
A prostate-specific antigen–activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer (2007) (49)
Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1‐13.2 (1999) (48)
Enzymatically active prostate‐specific antigen promotes growth of human prostate cancers (2011) (48)
Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. (2009) (47)
Activation of programmed (apoptotic) cell death for the treatment of prostate cancer. (1996) (47)
Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. (2020) (47)
Modulating paclitaxel bioavailability for targeting prostate cancer. (2007) (46)
Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity. (2009) (46)
Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response (2010) (46)
Lenalidomide in Nonmetastatic Biochemically Relapsed Prostate Cancer: Results of a Phase I/II Double-Blinded, Randomized Study (2010) (46)
Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. (2020) (45)
Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human (2006) (45)
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. (2007) (44)
Clinical activity of enzalutamide in Docetaxel‐naïve and Docetaxel‐pretreated patients with metastatic castration‐resistant prostate cancer (2014) (44)
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. (2021) (44)
Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. (2006) (43)
Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer. (2004) (42)
Role of androgen receptor splice variant 7 (AR-V7) in prostate cancer resistance to 2nd generation androgen receptor signaling inhibitors (2020) (42)
Prostate‐specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate‐targeted PSA/KLK2 double transgenic mice (2010) (41)
A Phase I Study to Assess the Safety and Cancer‐Homing Ability of Allogeneic Bone Marrow‐Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer (2019) (41)
Activation of latent protease function of pro‐hk2, but not pro‐PSA, involves autoprocessing (2001) (40)
Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer (2019) (38)
Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. (2013) (38)
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. (2012) (37)
Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells (2009) (37)
A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer. (2002) (36)
A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. (2020) (36)
Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer (2010) (36)
Prostate‐specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo (2003) (35)
Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial (2017) (35)
HIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides. (2009) (33)
Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value? (2000) (33)
AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC). (2015) (32)
Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase. (2005) (32)
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint (2007) (31)
Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells (1999) (30)
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. (2008) (30)
Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience (2019) (30)
Design, synthesis, and evaluation of pH-dependent hydrolyzable emetine analogues as treatment for prostate cancer. (2012) (29)
The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen Deprivation (2011) (29)
Challenges of conducting clinical trials of natural products to combat cancer. (2016) (29)
CCAAT/Enhancer Binding Protein β Controls Androgen Deprivation-Induced Senescence in Prostate Cancer Cells (2015) (29)
Cytotoxic phenylpropanoids and an additional thapsigargin analogue isolated from Thapsia garganica. (2006) (29)
Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC). (2014) (29)
Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer. (2009) (29)
Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer. (1998) (27)
A combinatorial approach to the selective capture of circulating malignant epithelial cells by peptide ligands. (2005) (27)
Engineering Enzymatically Activated “Molecular Grenades” for Cancer (2012) (26)
The role of prostate‐specific antigen in the clinical evaluation of prostatic disease (2004) (25)
Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer. (2017) (25)
Anti‐tumor effect of combination therapy with intratumoral controlled‐release paclitaxel (PACLIMER® microspheres) and radiation (2004) (24)
Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts. (2002) (24)
Mechanistic insights into the inhibition of prostate specific antigen by β‐lactam class compounds (2007) (24)
Iterative design of emetine‐based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy (2016) (24)
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy (Science Translational Medicine) (2012) (23)
The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer (2015) (23)
Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer. (2011) (22)
Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)‐activated prodrug in murine xenograft models of human cancer (2014) (22)
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial (2012) (22)
Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT (2019) (22)
Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate (2017) (21)
Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto). (2009) (21)
Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. (2019) (21)
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE) (2017) (21)
Prostate cancer: where are we and where are we going? (1997) (21)
AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): Expanded analysis of the Johns Hopkins cohort. (2016) (20)
Proteolysis of Complement Factors iC3b and C5 by the Serine Protease Prostate-Specific Antigen in Prostatic Fluid and Seminal Plasma (2013) (20)
Phase II Evaluation of Docetaxel Plus Exisulind in Patients With Androgen Independent Prostate Carcinoma (2006) (19)
The association of sex steroid hormone concentrations with non‐alcoholic fatty liver disease and liver enzymes in US men (2020) (19)
Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. (2020) (19)
Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell lines. (2015) (18)
Detection fidelity of AR mutations in plasma derived cell-free DNA (2017) (17)
Fatty Acid Synthesis in Prostate Cancer: Vulnerability or Epiphenomenon? (2021) (17)
Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors. (2013) (17)
Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer (2020) (17)
Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives. (2017) (16)
A pilot study of prostate‐specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer (2019) (16)
Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer. (2017) (16)
Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity (2007) (15)
Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer (2021) (15)
Synthesis and screening of a random dimeric peptide library using the one-bead-one-dimer combinatorial approach. (2006) (15)
Clinical Applications of Molecular Imaging in the Management of Prostate Cancer. (2017) (14)
Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer (2017) (14)
Patterns of recurrence and modes of progression after metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer (2020) (14)
Molecular insights into substrate specificity of prostate specific antigen through structural modeling (2009) (14)
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS) (2020) (13)
Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer (2018) (13)
Extended-release PEG-luciferin allows for long-term imaging of firefly luciferase activity in vivo. (2009) (12)
Synthesis and cytotoxic activities of some 2-Arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines (2012) (12)
PSA‐alpha‐2‐macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones (2018) (11)
Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT (2019) (11)
Bipolar androgen therapy in the treatment of prostate cancer. (2018) (11)
Protease-Activated Pore-Forming Peptides for the Treatment and Imaging of Prostate Cancer (2014) (10)
OC-0505: Interim results of a randomized trial of observation versus SABR for oligometastatic prostate cancer (2018) (10)
Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy. (2020) (10)
Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial. (2012) (10)
Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy. (2021) (10)
Apoptotic pathways in prostate cancer (2001) (9)
Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer (2021) (8)
Targeting the spectrum of immune checkpoints in prostate cancer (2021) (7)
A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. (2020) (7)
The genetics of programmed (apoptotic) cell death. (1995) (7)
Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC). (2019) (7)
A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. (2019) (7)
Erratum: Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer (Prostate (1996) 28 (251-265)) (1996) (7)
Trypsin‐like proteolytic contamination of commercially available psa purified from human seminal fluid (2012) (7)
Apoptosis in hormone-responsive malignancies. (1997) (7)
A Phase II Trial of Temozolomide and IFN-α in Patients with Advanced Renal Cell Carcinoma (2004) (6)
Targeted delivery of cytotoxic proteins to prostate cancer via conjugation to small molecule urea-based PSMA inhibitors (2021) (6)
Left Posterior Fascicular Block Due to High-Dose lnterleukin-2 (2008) (6)
Abstract B244: A first-in-human phase 1 clinical study of G-202, a thapsigargin-based Prostate-Specific Membrane Antigen (PSMA) activated prodrug, in patients with advanced solid tumors. (2013) (6)
Androgen Deprivation Strategies in the Treatment of Advanced Prostate Cancer (2003) (6)
A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma. (2004) (6)
COMBAT-CRPC: Concurrent administration of bipolar androgen therapy (BAT) and nivolumab in men with metastatic castration-resistant prostate cancer (mCRPC). (2021) (6)
7047 POSTER A Phase I Pharmacodynamic Dose Escalation Study of Steroid Sulphatase Inhibitor Irosustat in Patients With Prostate Cancer (2011) (5)
The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications (2022) (5)
Prospective , Randomized , Double-Blind , Vehicle Controlled , Multicenter Phase IIb Clinical Trial of the Pore Forming Protein PRX 302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia (2013) (5)
PSA-selective activation of cytotoxic human serine proteases within the tumor microenvironment as a therapeutic strategy to target prostate cancer (2018) (5)
Bipolar androgen therapy (BAT): A patient's guide (2022) (5)
798OAR-V7 SPLICE VARIANT AND RESISTANCE TO ENZALUTAMIDE AND ABIRATERONE IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): OVERALL SURVIVAL RESULTS (2014) (5)
An IL‐2 proaerolysin fusion toxin that selectively eliminates regulatory t cells to enhance antitumor immune response (2019) (5)
Prostate cancer androgen receptor activity dictates efficacy of Bipolar Androgen Therapy (2022) (4)
Overview of Regulation of Systemic Androgen Levels (2003) (4)
Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy (2021) (4)
Abstract 2910: Androgen receptor splice variant-7 predicts resistance to enzalutamide in patients with castration-resistant prostate cancer (2014) (4)
Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss (2022) (3)
Phase II study of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) and progression on enzalutamide (enza). (2017) (3)
Mutational Analysis of Prostate‐Specific Antigen Defines the Intrinsic Proteolytic Activity of the proPSA Zymogen (2016) (3)
The effect of PSA frequency and duration on PSA doubling time (PSADT) calculations in men with biochemically recurrent prostate cancer (BRPC) after definitive local therapy. (2012) (3)
A randomized double blind phase I-II study to determine the tolerability/efficacy of two different doses of lenalidomide (L), CC- 5013, in biochemically relapsed (BR) prostate cancer (PC) patients (pts) (M0) after local treatment (LT). (2009) (3)
Mipsagargin: The Beginning-Not the End-of Thapsigargin Prodrug-Based Cancer Therapeutics. (2021) (3)
Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC (2022) (3)
Prostate-Specific Membrane Antigen (PSMA) targeted prodrug “smartbombs” as therapy for prostate cancer (2006) (2)
Abstract 517: Supraphysiological androgens activate innate immune signaling in prostate cancer (2019) (2)
Apoptotic Pathways in Normal Prostate and Prostate Cancers (1999) (2)
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA) (2019) (2)
Androgen Deprivation Strategies for the Treatment of Recurrent and Metastatic Prostate Cancer (2003) (2)
Testosterone: Testosterone and the prostate (2012) (2)
Phase I dose-escalation study of AGS-PSCA, an anti-PSCA human antibody, in castration-resistant prostate cancer (2007) (2)
Androgen Receptor Splice Variants Are Not Substrates of Nonsense‐Mediated Decay (2017) (2)
Interim Results of a Randomized Trial of Observation Versus SABR for Castration-Sensitive Oligometastatic Prostate Cancer (2018) (2)
Abstract 16: Mutational analysis of PSA reveals its zymogen intrinsic activity . (2013) (2)
From Plant to Patient: Thapsigargin, a Tool for Understanding Natural Product Chemistry, Total Syntheses, Biosynthesis, Taxonomy, ATPases, Cell Death, and Drug Development. (2021) (2)
Abstract 2076: Albumin-linked proaerolysin based molecular grenades: A systemic therapeutic for disseminated castration resistant prostate cancer (2016) (2)
A phase II evaluation of imatinib mesylate (G) in stage M0 prostate cancer (PC) patients (pts) on hormonal therapy (HT) with evidence of biochemical relapse. (2006) (2)
High dose testosterone in men with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination deficiency (HRD). (2019) (2)
A pilot study of supraphysiologic testosterone (T) and oral etoposide (E) in men with castrate-resistant prostate cancer (CRPC). (2014) (2)
Supraphysiological testosterone induces ferroptosis and activates NF-kappaB mediated immune pathways in prostate cancer through nucleophagy (2020) (2)
A Phase II Study of Imatinib Mesylate in Prostate Cancer Patients With Evidence of Biochemical Relapse Following Definitive Radical Retropubic Prostatectomy or Radiation Therapy (2005) (2)
TRANSFORMER: Bipolar androgen therapy (BAT) versus enzalutamide (E) for castration-resistant metastatic prostate cancer (mCRPC). (2020) (2)
Phase I trial with a combination of docetaxel and 153Sm- EDTMP in patients (pts) with castration-resistant metastatic prostate cancer (mCRPC). (2009) (2)
A phase II study of rapid cycling high dose testosterone (Bipolar Androgen Therapy) in men with metastatic castrate-resistant prostate cancer (mCRPC) resistant to abiraterone and/or enzalutamide (2016) (2)
A phase II trial of rapid androgen cycling and docetaxel (Doc) in prostate cancer patients with a rising prostate-specific antigen (PSA) in the noncastrate state (2007) (2)
A randomized phase II study comparing bipolar androgen therapy vs. enzalutamide in asymptomatic men with castration resistant metastatic prostate cancer: The TRANSFORMER trial. (2015) (2)
Abstract IA09: A phase II trial to promote recovery from COVID-19 with endocrine therapy (2020) (1)
Abstract 699: Mesenchymal stem cells (MSC) as cell-based vectors for PSA-activated proaerolysin to sites of prostate cancer (2014) (1)
Pharmacologic Approaches to Lower Circulating Androgen (2003) (1)
A phase I trial of muscadine grape skin in men with biochemically recurrent prostate cancer. (2014) (1)
Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU‐AA‐302 (2019) (1)
Pharmacokinetics , Biodistribution , andAntitumor Efficacyof aHumanGlandularKallikrein 2 ( hK 2 )-ActivatedThapsigargin Prodrug (2006) (1)
RESTORE: A single-arm, open-label phase II trial of bipolar androgen therapy (BAT) in men with metastatic castration resistant prostate cancer (mCRPC)—A comparison of post-abiraterone (Abi) versus post-enzalutamide (Enza) patients (Pts). (2020) (1)
Abstract 2067: Attacking prostate cancer with a prodrug-doped cellular Trojan horse (2016) (1)
Design, synthesis and evaluation of pH-dependent hydrolysable emetine analogs as treatment for prostate cancer (2013) (1)
Phase I/II double-blinded randomized study to determine the tolerability and efficacy of two different doses of lenalidomide (Len) in biochemically relapsed prostate cancer (BRPC) (M0) patients (pts). (2010) (1)
A Thapsigargin Prodrug Produces Sustained Growth Inhibition and Substantial Regression of Human Breast Cancers In Vivo with Minimal Host Toxicity. (2009) (1)
Mechanism of Androgen Action (2003) (1)
1787 EVALUATION OF TRANSPERINEAL PROSTATIC ADMINISTRATION OF A PSA-ACTIVATED PROTOXIN (PRX302) IN MEN WITH LUTS SECONDARY TO BPH (2010) (1)
Metastasis Directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-Resistant Prostate Cancer (2020) (1)
MP-06.13: PRX302 is a Transperineally Administered, PSA-Activated Protoxin that Produces Symptomatic Relief in Men with Moderate to Severe BPH (2009) (1)
Phase I trial of docetaxel (D) plus samarium153 (Sm 153) in patients (pts) with hormone refractory prostate cancer (HRPC) (2007) (1)
PSA provocation by bipolar androgen therapy may predict duration of response to first‐line androgen deprivation: Updated results from the BATMAN study (2022) (1)
601 A First-in-human, Phase 1 Clinical Study of the Safety, Tolerability and Pharmacokinetics (PK) of G-202, a Thapsigargin-based PSMA-activated Prodrug, in Patients with Advanced Solid Tumors (2012) (1)
A prostate-specific membrane antigen (PSMA) activated thapsigargin prodrug demonstrates antitumor efficacy against human breast cancer xenografts (2008) (1)
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial (2023) (1)
GERMLINE MUTATIONS IN DNA REPAIR GENES ARE SIGNIFICANTLY ENRICHED IN LETHAL PROSTATE CANCER AND ARE ASSOCIATED WITH DISEASE SURVIVAL: MP57‐01 (2017) (1)
Pancreas Cancer Molecular Targets for Therapy (2011) (1)
PtdIns 3-kinase (2011) (1)
The unfolding treatment landscape for men with castration-resistant prostate cancer. (2011) (1)
In Reply (2019) (1)
A phase II study of muscadine grape skin extract in men with biochemically recurrent prostate cancer. (2017) (1)
Molecular and Cellular Pathobiology Single Copies of Mutant KRAS and Mutant PIK 3 CA Cooperate in Immortalized Human Epithelial Cells to Induce Tumor Formation (2013) (1)
Patterns of metastatic disease progression after treatment with first-line enzalutamide or abiraterone in castration-resistant prostate cancer (CRPC). (2016) (1)
Cellular Organization of the Normal Prostate (2003) (1)
Generation of Transgenic Animals Producing Ezymatically Active Prostate-Specific Antigen (PSA) in Normal and Malignant Prostate Tissue (2005) (0)
297 Effectiveness of Acute Cycling of Supraphysiologic Testosterone Given Together with Etoposide in Men with Castration Resistant Prostate Cancer (2012) (0)
Visceral metastases on abiraterone vs. placebo: A post-hoc analysis of mode of radiographic progression in COU-AA-302. (2018) (0)
Selective Activation of a Perforin-Granzyme B Fusion Protein Toxin by PSA as Therapy for Metastatic Prostate Cancer (2016) (0)
Carcinoma Cell Growth Tyrosine Kinase Activity and Block Medullary Thyroid CEP-701 and CEP-751 Inhibit Constitutively Activated RET Updated (2003) (0)
Enzymatic Activation of Proteasome Inhibitor Prodrugs by Prostate-Specific Antigen as Targeted Therapy for Prostate Cancer (2000) (0)
WNT activating pathway mutations confer resistance to first-line antiandrogen therapy in castration-resistant prostate cancer (CRPC). (2019) (0)
508 STEROIDOGENIC PROPERTIES OF PROSTATE CANCER CELL-LINES: PROOF FOR INTRACRINE ANDROGEN METABOLISM? (2009) (0)
Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer. (2023) (0)
A novel thapsigargin prodrug demonstrates antitumor activity against a panel of human cancer xenografts (2007) (0)
434 Bipolar androgen therapy for men with castration sensitive and castration resistant prostate cancer: Reversing resistance and maintaining sensitivity to androgen ablative therapies (2014) (0)
Denmeade Endothelial Cell Prodrug for Cancer Therapy Activated Tumor − Engineering a Prostate-Specific Membrane Antigen (2012) (0)
Primary Cancer Site (2011) (0)
Alternative Strategies for Androgen Deprivation (2003) (0)
Bipolar androgen therapy (BAT) in men with hormone sensitive (HS) prostate cancer (PC). (2016) (0)
PSMA-Activated Imaging Agents for Prostate Cancer (2008) (0)
Abstract 4345: Molecular pathology studies reveal PD1+ CD8 T cell density correlates with response to supraphysiological testosterone treatment in pre-treatment biopsies and MYC mRNA and protein correlate with response after treatment (2023) (0)
Abstract 5699: Mesenchymal stem cells (MSCs) as a selective delivery vehicle for a PSA-activated protoxin for advanced prostate cancer (2012) (0)
Compositions et procedes destines au traitement du cancer (2007) (0)
Abstract 5953: Regulation of androgen receptor stability by nuclear export protein CRM1 (2020) (0)
Enzymatic Activation of Peptide Prodrugs by Prostate-Specific Membrane Antigen (PSMA) as Targeted Therapy for Prostate Cancer (2003) (0)
PSA doubling time (PSADT) and serum testosterone (T) during intermittent androgen deprivation (IAD) in patients with biochemically relapsed prostate cancer (BRCP; M0): Potential predictive implications. (2011) (0)
Abstract #1125: Fibroblast activation protein (FAP) as a mediator of TGF-\#946; activation (2009) (0)
Targeting the Human Complement Membrane Attack Complex to Selectively Kill Prostate Cancer Cells (2014) (0)
The natural history and clinical/molecular characterization of primary Gleason pattern 5 (G5) prostate cancer (PCa) treated with radical prostatectomy (RP). (2016) (0)
Abstract #4463: Targeted imaging of prostate cancer: the smart-bomb pro-drug delivery mechanism (2009) (0)
AD Award Number : DAMD 17-001-0028 TITLE : Enzymatic Activation of Proteasome Inhibitor Prodrugs by Prostate-Specific Antigen as Targeted Therapy for Prostate Cancer (0)
PSA-activated proaerolysin as a prostate specific cancer therapy (2006) (0)
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA) (2019) (0)
A PSA-ACTIVATED PROTOXIN (PRX302) ADMINISTERED TRANSPERINEALLY TO MEN WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA IS WELL TOLERATED AND EXHIBITS SIGNS OF ACTIVITY (2008) (0)
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial (2022) (0)
Targeting Mitochondrial Inhibitors for Metastatic Castrate-Resistant Prostate Cancer (2017) (0)
Abstract 2410: Supraphysiological androgens induce ferroptotic cell death in prostate cancer cells (2020) (0)
Crystal structures of SERCA in complex with inhibitors with potential as prostate cancer drugs (2008) (0)
Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors (2021) (0)
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS) (2020) (0)
Modes of Failure Following Metastasis Directed Therapy in Patients with Oligometastatic Hormone Sensitive Prostate Cancer: A Multi-institutional Analysis (2020) (0)
Development and characterization of prostate specific antigen inhibitors (2006) (0)
Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors (2021) (0)
Radiotherapy In The Definitive Management Of Oligometastatic Prostate Cancer (2019) (0)
PSA doubling time (PSADT) and serum testosterone (T) during intermittent androgen deprivation (IAD) in patients with biochemically relapsed prostate cancer (BRCP; M0): Potential predictive implications. (2011) (0)
Population Candidate Gene Association Study (2011) (0)
Safety and efficacy of ketoconazole (K) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Contemporary experience and prognostic indicators. (2011) (0)
Abstract 653: Molecular pathology of metastatic prostatic adenocarcinoma treated with bipolar androgen therapy (BAT) reveals a correlation between MYC mRNA and protein (2022) (0)
Safety and efficacy of ketoconazole (K) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Contemporary experience and prognostic indicators. (2011) (0)
Abstract 6055: Cell confluence growth tracking as a supplement assay for clonogenic assay in prostate cancer radiotherapy combination evaluation (2022) (0)
Advances in the understanding and treatment of prostate cancer (2006) (0)
Clinical Outcomes in Oligometastatic Prostate Cancer Following Definitive Radiation Therapy (2019) (0)
Efficacy of alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma immunotherapy in patients (pts) with refractory metastatic renal cell carcinoma (mRCC). (2019) (0)
MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression (2023) (0)
Abstract 2326: Loss of prostate-specific antigen slows growth and alters the extracellular proteome of LNCaP human prostate cancer cells (2010) (0)
526 POSTER A prostate-Specific Antigen (PSA) activated channel-forming toxin as therapy for prostatic disease (2006) (0)
A PSA-ACTIVATED PROTOXIN (PRX302) ADMINISTERED TRANSPERINEALLY TO MEN WITH BPH IS WELL TOLERATED AND INDUCES REDUCTION IN PROSTATE VOLUME AND SYMPTOMATIC RELIEF (2009) (0)
Abstract 1424: Fibroblast activation protein alpha (FAP): Targeting the reactive stroma as a novel prodrug therapy (2010) (0)
Bioprecurseurs a specificite tissulaire (1998) (0)
Regulating Prostate Cancer Sensitivity to Chemotherapy through Translational Control of CCAAT Enhancer Binding Proteins (2015) (0)
TITLE: Targeting the Human Complement Membrane Attack Complex to Selectively Kill Prostate Cancer Cells (2012) (0)
Updated analyses for RESTORE cohort C: A trial of bipolar androgen therapy for patients with newly castration-resistant prostate cancer. (2022) (0)
Molecular and clinical characterization of metastatic castration-resistant prostate cancer (mCRPC) patients achieving deep PSA responses to bipolar androgen therapy (BAT). (2021) (0)
527 POSTER Fibroblast Activation Protein (FAP) activated anti-stromal prodrug therapy for cancer (2006) (0)
Defining the role of NDRG1 in prostate cancer (2007) (0)
894 TARGETED IMAGING OF PROSTATE CANCER: SMART-BOMB PRO-DRUG MECHANISM (2009) (0)
Cancer Therapy : Clinical Phase II Study of Androgen Synthesis Inhibition with Ketoconazole , Hydrocortisone , and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer (2009) (0)
Definition of Androgen Responsiveness on a Cellular Basis (2003) (0)
alidomide in Nonmetastatic Biochemically Relapsed state Cancer: Results of a Phase I/II (2010) (0)
Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer (2020) (0)
Hormone Resistance in Prostate Cancer (2002) (0)
Rapid cycling high dose testosterone (Bipolar Androgen Therapy) as therapy for men with metastatic castrate-resistant prostate cancer (mCRPC) (2016) (0)
Genomic determinants of sensitivity to bipolar androgen therapy (BAT) in castrate-resistant prostate cancer (CRPC). (2019) (0)
Phase I dose-escalation study of AGS-1C4D4, an anti-PSCA human antibody in castration-resistant prostate cancer (CRPC). (2010) (0)
Identification of Breast Cancer - Specific Proteolytic Activities for Targeted Prodrug Activation (2006) (0)
Genomic analysis and clinical outcomes of Primary Gleason Pattern 5 (PG5) prostate cancer (PCa) treated with radical prostatectomy (RP). (2019) (0)
Abstract 5058: Expansion and validation of the prostate-specific antigen substrate degradome. (2013) (0)
Abstract 2404: Increased mitochondrial DNA copy number occurs during prostate cancer progression and in cancer precursor lesions across multiple organs (2021) (0)
TISSUE SPECIFIC PRODRUG CROSS REFERENCE TO RELATED APPLICATIONS (2017) (0)
Proaerolysine contenant des sequences d'activation de protease et procedes destines au traitement du cancer de la prostate (2002) (0)
Correlation between serum PSA and testosterone (T) kinetics in patients (pts) with biochemically relapsed prostate cancer (BRPC) (M0), after local treatment (tx), treated with intermittent androgen deprivation (IAD). (2010) (0)
TITLE: Enzymatic Activation of Peptide Prodrugs by Prostate-Specific Membrane Antigen (PSMA) as Targeted Therapy for Prostate Cancer (2006) (0)
Phase II evaluation of docetaxel (D) plus exisulind (E) in patients (pts) with androgen independent prostate carcinoma (AIPC) (2005) (0)
What Was the Prostate? (2021) (0)
Plasma Antigen in Prostatic Fluid and Seminal C 5 by the Serine Protease Prostate-Specific Proteolysis of Complement Factors iC 3 b and (2013) (0)
Abstract 85: CCAAT/enhancer binding protein beta facilitates castrate-resistant prostate cancer cell growth and sensitivity to mTOR inhibitors (2015) (0)
Clinical Cancer esearch cer Therapy : Clinical alidomide in Nonmetastatic Biochemically Relapsed state Cancer : Results of a Phase I / II R ble-Blinded , Randomized Study (2010) (0)

This paper list is powered by the following services:

Other Resources About Samuel Denmeade

en.wikipedia.org

What Schools Are Affiliated With Samuel Denmeade?

Samuel Denmeade is affiliated with the following schools: